EHMT2 and colorectal carcinoma: The high-expression EHMT2 group showed a poor prognosis compared with the low-expression EHMT2 group (p = 0.043; Fig. 7A), indicating that EHMT2 is an attractive therapeutic target for CRC treatment and can be used to prevent CRC.